Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Progestogen-only contraception

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    496 result(s) found for: Progestogen-only contraception. Displaying page 9 of 25.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2018-001690-25 Sponsor Protocol Number: CT-P17-3.1 Start Date*: 2018-11-13
    Sponsor Name:Celltrion, Inc
    Full Title: A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Efficacy and Safety of CT-P17 with Humira when Co-administered with Methotrexate in Patients with Moderate to Severe Active R...
    Medical condition: Moderate to Severe Active Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2004-004984-32 Sponsor Protocol Number: NKF100096 Start Date*: 2005-06-10
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects with Major Depres...
    Medical condition: Major Depressive Disorder (MDD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed) SE (Completed) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000545-39 Sponsor Protocol Number: DERMAQ-001 Start Date*: 2018-04-30
    Sponsor Name:ASL 1 AVEZZANO-SULMONA-L'AQUILA
    Full Title: A randomized half-side comparative study of Methyl aminolevulinate (MAL, Metvix®) Daylight photodynamic therapy (DL-PDT) with or without pre-treatment with calcitriol (Silkis®) for Actinic Keratosi...
    Medical condition: Actinic Keratosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004858 10020648 Hyperkeratoses HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000660-25 Sponsor Protocol Number: CT-P17_3.2 Start Date*: 2019-07-09
    Sponsor Name:CELLTRION, Inc.
    Full Title: A Phase III, Open-label, Single-arm, Multiple-dose Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients with Moderate to Severe Active Rheumatoid Arthritis
    Medical condition: Moderate to Severe Active Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-000998-72 Sponsor Protocol Number: 4083-006 Start Date*: 2019-01-22
    Sponsor Name:Kyowa Kirin Co., Ltd.
    Full Title: A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects with Moderate to Severe Atopic Dermatitis
    Medical condition: Moderate to Severe Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005855-16 Sponsor Protocol Number: NKT102552 Start Date*: 2006-03-20
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for...
    Medical condition: Postoperative Nausea and Vomiting (PONV)
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) HU (Completed) ES (Completed) CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002369-23 Sponsor Protocol Number: 1289-0049 Start Date*: 2019-05-27
    Sponsor Name:Boehringer Ingelheim
    Full Title: A phase II randomised, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered BI 409306 during a 28-week treatment period as adjunctive the...
    Medical condition: schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10064337 Schizophrenia relapse LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004070-22 Sponsor Protocol Number: CV-NCOV-003 Start Date*: 2021-04-12
    Sponsor Name:CureVac AG
    Full Title: COVID-19: A Phase 3 multicenter clinical trial to evaluate the safety, reactogenicity and immunogenicity of the investigational SARS-CoV-2 mRNA vaccine CVnCoV in adults 18 years of age and above wi...
    Medical condition: Vaccination for prophylaxis of COVID-19 (adults with co morbidities)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084464 COVID-19 immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000100-37 Sponsor Protocol Number: V01-126A-202 Start Date*: 2022-01-03
    Sponsor Name:Bausch Health Americas, Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Clinical Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel (0.3% adapalene/2.5% BPO), in the Treat...
    Medical condition: Acne Vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10000519 Acne vulgaris LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001411-82 Sponsor Protocol Number: HIPRA-HH-1 Start Date*: 2021-08-11
    Sponsor Name:LABORATORIOS HIPRA, S.A.
    Full Title: A phase I/IIa study to evaluate safety and immunogenicity of recombinant protein RBD fusion dimer candidate vaccine against SARS-CoV-2 in adult healthy volunteers.
    Medical condition: SARS-CoV-2
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002418-18 Sponsor Protocol Number: 2021-10 Start Date*: 2022-11-09
    Sponsor Name:University Hospital Tübingen
    Full Title: AmaNtadine for NeuroenhancEment in acutE patients Study - A prospective pilot proof of concept phase IIb study in intensive and intermediate care unit patients (ANNES)
    Medical condition: Patients on Intermediate Care and Intensive Care Unit (IMC and ICU) with unresponsive wakefulness syndrome not otherwise explained
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001316-26 Sponsor Protocol Number: APHP200007 Start Date*: 2022-09-12
    Sponsor Name:Assistance Publique Hôpitaux de Paris / DRCI
    Full Title: Multicenter, randomized, prospective trial comparing the Efficacy and Safety of Adalimumab to that of Tocilizumab in severe uveitis of Behçet’s disease UVB Study
    Medical condition: severe uveitis of Behçet’s disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10071139 Behcet's uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001838-11 Sponsor Protocol Number: APHP211055 Start Date*: 2022-10-20
    Sponsor Name:APHP DRCI
    Full Title: Evaluation of low dose colchicine and ticagrelor in prevention of ischemic stroke in patients with stroke due to atherosclerosis. “Reducing inflammation in ischemic stroke with colchicine (riisc),...
    Medical condition: Evaluation of low dose colchicine and ticagrelor in prevention of ischemic stroke in patients with stroke due to atherosclerosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005362-18 Sponsor Protocol Number: HBIGforcure Start Date*: 2022-04-13
    Sponsor Name:Hannover Medical School
    Full Title: Hepatitis B immunoglobulins to induce HBsAg clearance in patients with chronic hepatitis B
    Medical condition: HBeAg negative patients with chronic HBV infection will be allocated into two different cohorts, cohort A and cohort B.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10022891 - Investigations 10052297 Hepatitis B e antigen negative PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002777-95 Sponsor Protocol Number: 2020STSNeoadjuvant Start Date*: 2020-10-29
    Sponsor Name:Oslo University Hospital
    Full Title: Sequential neoadjuvant ifosfamide and doxorubicin in localized high-grade soft tissue sarcoma of extremities and trunk wall
    Medical condition: Soft Tissue Sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075333 Soft tissue sarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001728-20 Sponsor Protocol Number: RACE Start Date*: 2020-01-17
    Sponsor Name:Ruprecht-Karls-Universität Heidelberg
    Full Title: - RACE - Neoadjuvant Radiochemotherapy versus Chemotherapy for Patients with Locally Advanced, Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) A randomized phase III j...
    Medical condition: Locally Advanced, Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-003725-22 Sponsor Protocol Number: KKS-306 Start Date*: 2023-04-20
    Sponsor Name:Justus-Liebig-University Gießen
    Full Title: Acute effect of iloprost (Ventavis®) inhalation in patients with exercise-induced pulmonary hypertension after a COVID-19 infection
    Medical condition: Exercise-induced pulmonary hypertension after a COVID-19 infection
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    24.1 100000004862 10085867 Post-COVID-19 syndrome LLT
    24.1 100000004862 10085868 Long COVID-19 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003940-61 Sponsor Protocol Number: MINT Start Date*: 2020-12-07
    Sponsor Name:Uppsala county council
    Full Title: Metformin Intervention in children and adolescents with obesity. A parallel, three arms, randomized, 6 months, multi-center study with metformin extended release (XR) plus lifestyle or metformin i...
    Medical condition: Children and Adolscents with obesity
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000028-36 Sponsor Protocol Number: P3-IMU-838-RMS-01 Start Date*: 2022-04-21
    Sponsor Name:Immunic AG
    Full Title: A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1)
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Trial now transitioned) BG (Trial now transitioned) GR (Completed) DE (Trial now transitioned) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004805-30 Sponsor Protocol Number: CLN-PXT3003-06 Start Date*: Information not available in EudraCT
    Sponsor Name:Pharnext SCA
    Full Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth type 1A (CMT1A)
    Medical condition: Charcot Marie Tooth Type 1A
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10008414 Charcot-Marie-Tooth disease LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) NL (Prematurely Ended) DK (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) FR (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 00:21:36 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA